candesartan has been researched along with Anterior Circulation Transient Ischemic Attack in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with candesartan, pioglitazone, and their combination resulted in significantly reduced mRNA expression of the inflammatory markers CXCL1 and TNFalpha in vivo (P<0." | 1.35 | Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. ( Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A, 2008) |
| "Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion." | 1.32 | The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. ( Doerfler, A; Engelhorn, T; Forsting, M; Goerike, S; Heusch, G; Okorn, C; Schulz, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, T | 1 |
| Rahman, M | 1 |
| Hayashi, K | 1 |
| Takeda, K | 1 |
| Higaki, J | 1 |
| Sato, T | 1 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Ogihara, T | 1 |
| Fukiyama, K | 1 |
| Fujishima, M | 1 |
| Saruta, T | 1 |
| Engelhorn, T | 2 |
| Goerike, S | 1 |
| Doerfler, A | 2 |
| Okorn, C | 1 |
| Forsting, M | 1 |
| Heusch, G | 2 |
| Schulz, R | 2 |
| Schmerbach, K | 1 |
| Schefe, JH | 1 |
| Krikov, M | 1 |
| Müller, S | 1 |
| Villringer, A | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Thoene-Reineke, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
3 other studies available for candesartan and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2004 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Benzimidazoles; Biph | 2008 |